Aligos Therapeutics, Inc. - Common stock (ALGS) earnings
ALGS earnings moved a median of +3.20% by the close. Quarterly and annual ALGS reports and results, each read against the price at its own news timestamp. Back to the ALGS overview →
21 measured ALGS earnings events.
Where these ALGS earnings landedvs 21 measured ALGS earnings reactions
| Middle 50% of ALGS earnings reactions | -0.26% to +9.25% |
|---|---|
| Median reaction (to close) | +3.20% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 ALGS earnings events with a measured close landed between -0.26% and +9.25%; 67% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results | Press release | +2.87% | +31.82% | |
| Form 10-Q Aligos Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +2.87% | +31.82% | |
| Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results | Press release | -2.46% | +5.40% | |
| Form 10-Q Aligos Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -2.46% | +5.40% | |
| Form 10-K Aligos Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.00% | -2.06% | |
| Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results | Press release | -8.27% | +3.20% | |
| Form 10-Q Aligos Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -8.27% | +3.20% | |
| Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results | Press release | +1.33% | +5.17% | |
| Form 10-Q Aligos Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +1.33% | +5.17% | |
| Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results | Press release | -3.00% | -15.03% | |
| Form 10-Q Aligos Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | -3.00% | -15.03% | |
| Form 10-K Aligos Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -1.32% | -14.39% | |
| Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results | Press release | +1.70% | +9.25% | |
| Form 10-Q Aligos Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +1.70% | +9.25% | |
| Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results | Press release | +3.27% | +17.28% | |
| Form 10-Q Aligos Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +3.27% | +17.28% | |
| Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results | Press release | +4.43% | -0.26% | |
| Form 10-Q Aligos Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +4.43% | -0.26% | |
| Form 10-K Aligos Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -4.48% | +0.00% | |
| Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results | Press release | -2.67% | +1.36% | |
| Form 10-Q Aligos Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | -2.67% | +1.36% |
Keep exploring
More ALGS: analyst actions → · SEC filings → · ALGS overview →